Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Brensocatib Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

NCT05826574
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Rifampin, Esomeprazole
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

NCT06178783
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2024 · Synced Sep 2, 2026, 2:26 PM EDT
Terminated Phase 2 Interventional

A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT06685835
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brensocatib, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
26
States / cities
Phoenix, Arizona • Sacramento, California • Coral Gables, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants

NCT06344728
View directory record Official record
Conditions
Healthy Participants
Interventions
Brensocatib Oral Solution, Brensocatib Oral Tablet
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT03218917
View directory record Official record
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Brensocatib 10 mg, Brensocatib 25 mg, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Peoria, Arizona • Newport Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

NCT05965570
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Clarithromycin
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05517525
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Brensocatib
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Rialto, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

NCT05652257
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-brensocatib
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

NCT05355935
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Brensocatib, Moxifloxacin, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional

A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

NCT06013241
View directory record Official record
Conditions
Chronic Rhinosinusitis Without Nasal Polyps
Interventions
Brensocatib, Placebo, Mometasone furoate nasal spray (MFNS)
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
27
States / cities
Tucson, Arizona • Roseville, California • Upland, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

NCT05927597
View directory record Official record
Conditions
Healthy Volunteers
Interventions
INS1007, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 50 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

NCT05090904
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Brensocatib, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Gainesville, Florida • Augusta, Georgia • Glenview, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT04594369
View directory record Official record
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Brensocatib 10 mg, Brensocatib 25 mg, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
12 Years to 85 Years
Enrollment
1,767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
67
States / cities
Birmingham, Alabama • Conway, Arkansas • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 2, 2026, 2:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment

NCT05673603
View directory record Official record
Conditions
Renal Impairment
Interventions
Brensocatib
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Orlando, Florida • Tampa, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 2, 2026, 2:26 PM EDT